Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease

Journal of Hypertension

Volumn 28, Issue 9, 2010, Pages 1920-1927

  Hausberg, Martin ^a,d   Tokmak, Faruk ^b   Pavenstädt, Hermann ^a   Krämer, Bernhard K ^b   Rump, Lars Christian ^b,c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Department of Internal Medicine I   (Germany)

Author keywords

end stage renal disease; microneurography; moxonidine; sympathetic nervous system

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MOXONIDINE; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORONARY HEMODYNAMICS; DIAGNOSIS; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HYPOTHESIS; KIDNEY FAILURE; LABORATORY TEST; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MICRONEUROGRAPHY; PERONEUS NERVE; PRIORITY JOURNAL; PROGNOSIS; SYMPATHETIC TONE; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 77955853679     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c2100     Document Type: Article

References (40)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
3. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12:2427-2433.
4. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
5. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
6. Dinenno FA, Jones PP, Seals DR, Tanaka H. Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am J Physiol Heart Circ Physiol 2000; 278:H1205-1210.
7. Peng T, Jiang X, Wang Y, Hand A, Gillies C, Cone RE, et al. Sympathectomy decreases and adrenergic stimulation increases the release of tissue plasminogen activator (t-pa) from blood vessels: Functional evidence for a neurologic regulation of plasmin production within vessel walls and other tissue matrices. J Neurosci Res 1999; 57:680-692.
8. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565.
9. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle sympathetic nerve activity and large artery mechanical vessel wall properties in renal transplant patients. J Hypertens 2002; 20:501-508.
10. Midtvedt K, Hartmann A, Bentdal O, Brekke IB, Fauchald P. Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996; 11:2045-2049.
11. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
12. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430.
13. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15:2902-2907.
14. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21:1709-1717.
15. Ligtenberg G, Barnas MG, Koomans HA. Intradialytic hypotension: new insights into the mechanism of vasovagal syncope. Nephrol Dial Transplant 1998; 13:2745-2747.
16. Siggard-Anderson J. Venous occlusion pelthysmography on the calf. Dan Med Bull 1970; 17:1-68.
17. Hausberg M, Mark AL, Hoffman RP, Sinkey CA, Anderson EA. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens 1995; 13:1015-1021.
18. Wenzel RR, Mitchell A, Siffert W, Buhrmann S, Philipp T, Schafers RF. The i1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. Br J Clin Pharmacol 2004; 57:545-551.
19. Wenzel RR, Spieker L, Qui S, Shaw S, Luscher TF, Noll G. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 1998; 32:1022-1027.
20. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Mancia G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension 2001; 38:286-291.
21. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003; S88-S93.
22. Charkoudian N, Joyner MJ, Sokolnicki LA, Johnson CP, Eisenach JH, Dietz NM, et al. Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. J Physiol 2006; 572:821-827.
23. Converse RL Jr, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 1992; 90:1657-1665.
24. Ligtenberg G. Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Neth J Med 1999; 55:13-18.
25. Zilch O, Vos PF, Oey PL, Cramer MJ, Ligtenberg G, Koomans HA, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007; 25:1285-1289.
26. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-942.
27. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434-2439.
28. Kosch M, Levers A, Barenbrock M, Matzkies F, Schaefer RM, Kisters K, et al. Acute effects of haemodialysis on endothelial function and large artery elasticity. Nephrol Dial Transplant 2001; 16:1663-1668.
29. van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12 (Suppl 2):14-18.
30. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004; 65:700-704.
31. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 2003; 64:1472-1479.
32. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (moxcon). Eur J Heart Fail 2003; 5:659-667.
33. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25:878-882.
34. DiBona GF, Jones SY, Kopp UC. Renal mechanoreceptor dysfunction: an intermediate phenotype in spontaneously hypertensive rats. Hypertension 1999; 33:472-475.
35. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2:349-359.
36. Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol 1996; 491 (Pt 3):881-887.
37. Noll G, Wenzel RR, de Marchi S, Shaw S, Luscher TF. Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 1997; 95:2286-2292.
38. Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension 1984; 6:557-562.
39. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Luscher TF, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29:1607-1614.
40. Wenzel RR, Bruck H, Noll G, Schafers RF, Daul AE, Philipp T. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 2000; 35:S43-52.